Bismab-A (lintuzumab-Bi-213) - Actinium
Actinium: Future Leaders in the Biotech Industry (Actinium Pharmaceuticals) - Mar 27, 2015 - Discontinuation of development due to supply, logistics, and cost reasons 
Discontinued Oncology
http://www.actiniumpharma.com/wp-content/uploads/ATNM-Presentation-March.pdf
 
Mar 27, 2015
 
.
 
26a3412b-ad57-4fc1-b199-2420eddca104.jpg